Progyny, Inc. (PGNY) stock
PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 19/304% above fair value
$36.71−0.44 (-1.18%)
Close on Nov 17, 2026Market cap $2.82BP/E 39.9Yield –
Progyny r&d expenses
Research and development expenses are spending on new products and technology.
Progyny's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.80M. For fiscal 2025 it was $9.50M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.30M | +43.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.80M | +86.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.10M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.60M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.30M | – |
| Q1 FY2025 | Mar 31, 2025 | $1.50M | – |
See a number that looks wrong?